Composition: Each sugar-coated tablet contains Quinine Sulphate BP 300 mg.
Therapeutic category: Antimalarial
Usage: Treatment of malaria in selected clinician-prescribed regimens.
Manufacturer: Healthy Life Pharma Pvt. Ltd.
Exporter: Healthy Inc
SKU: Quinine Sulphate Tablets
Quinine Sulphate Tablets BP – Manufacturer India is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Categories: Pharmaceutical Exporter India · Pharmaceutical Formulations India · WHO GMP Certified Formulations
Quinine sulphate is a cinchona-derived antimalarial medicine used in selected treatment regimens for malaria, particularly when recommended alternatives are unavailable or unsuitable. The supplied formulation is Glaquine — Quinine Sulphate Tablets BP 300 mg, a sugar-coated oral tablet. Healthy Life Pharma Pvt. Ltd. is identified as manufacturer and Healthy Inc as exporter. Current manufacturing approvals, certification and supply arrangements should be confirmed directly.
Oral quinine is not the first-line treatment for severe malaria: severe malaria requires urgent hospital care and parenteral artesunate where available. Quinine is not recommended for routine treatment of nocturnal leg cramps because serious adverse effects can outweigh benefits.
| Product name | Quinine Sulphate Tablets BP 300 mg |
|---|---|
| Brand reference | Glaquine (verify trademark and product authorization) |
| Composition | Each sugar-coated tablet contains Quinine Sulphate BP 300 mg |
| Dosage form | Sugar-coated oral tablet |
| Pharmacopoeial standard | BP (as supplied) |
| Therapeutic class | Antimalarial |
| SKU | Quinine Sulphate Tablets |
| Other strengths | 600 mg mentioned in source description; availability and formulation not verified |
| Packaging / shelf life | Confirm with approved pack specification and stability records; 36 months not independently verified |
Quinine has a pronounced bitter taste, making sugar coating relevant for palatability. Appropriate manufacture includes verified raw materials, validated mixing and compression, controlled coating and documented in-process testing. Product-specific controls for light and moisture exposure should follow stability data rather than assumed processes.
For export, packaging suitability, traceability and transport conditions should be evaluated for destination climates. Specific claims about opaque coatings, machinery, production capacity or WHO-GMP certification require current evidence.
Batch release should follow the approved BP monograph and registered specifications, including identification, assay, related substances, dissolution or disintegration as applicable, dosage-unit uniformity, coating integrity and packaging checks. Dihydroquinine and other related alkaloids should be assessed against the relevant current monograph. Do not assume universal assay limits or dissolution thresholds without checking the applicable specification.
Quinine acts against blood-stage malaria parasites, in part by interfering with haem detoxification. It may be used in selected regimens for Plasmodium falciparum malaria, generally together with an appropriate partner antibiotic under local treatment guidelines. It is not suitable as a stand-alone solution for every type of malaria.
Severe malaria is a medical emergency: parenteral artesunate is preferred where available, and oral tablets should not delay emergency treatment. Leg cramps are not an appropriate routine indication because quinine can cause serious cardiac and hematologic toxicity.
For B2B enquiries, request the approved product specification, batch certificate of analysis, manufacturing licence, current GMP evidence, applicable registration dossier, stability data and destination-country documentation. CTD/ACTD dossiers, COPP, Free Sale Certificates and specific shipping terms should be confirmed for the product and importing jurisdiction before any commitments are made.
Q: What is the supplied strength?
A: The supplied formulation specifies a sugar-coated Quinine Sulphate BP 300 mg tablet. A 600 mg variant was mentioned in descriptive text but is not confirmed by a composition.
Q: Is oral quinine the preferred treatment for severe malaria?
A: No. Severe malaria needs immediate hospital treatment; intravenous or intramuscular artesunate is generally preferred where available.
Q: Can quinine be used for night leg cramps?
A: Routine use is not recommended due to potentially life-threatening adverse reactions.
Q: What is cinchonism?
A: A collection of quinine-associated effects that can include tinnitus, headache, nausea and visual disturbance.
Quinine dosing depends on the malaria species, severity, local resistance, patient weight, pregnancy status, kidney function and the exact salt/formulation. It must be prescribed as part of an appropriate regimen, often with a partner medicine. The amount of quinine sulphate salt is not interchangeable milligram-for-milligram with quinine base or other quinine salts.
Swallow sugar-coated tablets as directed on the approved label. Do not crush or chew unless a pharmacist confirms it is appropriate. Do not self-treat suspected severe malaria or use quinine for leg cramps without specialist evaluation.
Cinchonism: ringing in the ears, headache, nausea, dizziness and visual disturbance. Serious risks: hypoglycaemia, QT prolongation and arrhythmia, immune thrombocytopenia, hemolysis, severe allergic reactions and drug interactions. Pregnancy-related malaria requires urgent clinician-directed therapy; maternal blood glucose monitoring may be important when quinine is used.
Seek immediate care for fainting, palpitations, confusion, unusual bruising or bleeding, severe rash, or signs of low blood sugar. Review interacting medicines and cardiac history before prescribing.
Store in the original, tightly closed package according to the approved product label. Protect from excess moisture and light where specified by stability studies. A universal “below 25°C” requirement should not be assumed without the registered label. Keep out of reach of children.